The Protocole review

The Protocole gives readers clear product-price labels, but the final bill and cancellation protection need more work. Obtain the initiation fee and the cutoff before clinical review in writing; the homepage’s promise of changes before shipment is broader than the refund policy.

The Protocole is a consumer telehealth and concierge platform operated by PeptideCo, Inc. Its terms identify Arora Health & Aesthetics, LLC as the clinical group responsible for safety assessments and medication recommendations. The platform and medical practice have different roles: a concierge response is not the same as an assessment by the clinician responsible for a prescription.

The menu includes compounded semaglutide, tirzepatide, NAD+ and sermorelin, with separate lower-dose GLP-1 listings. A menu is a description of what the business advertises, rather than confirmation that a particular product can be prescribed to an individual. The site names VialsRX as its compounding and dispensing pharmacy partner. That is a merchant disclosure, not independent verification of pharmacy licensing or a guarantee of the dispenser assigned to every order.

For a reader comparing services, the useful questions are who provides clinical care, what the selected purchase includes and which company handles a problem. The site answers some of those questions more clearly than the final charge and cancellation terms.

The public pathway begins with a health intake followed by review and approval from a licensed provider before a prescription is issued. An optional consultation route advertises a 30-minute video conversation for $50, credited toward an order if the person proceeds. The homepage FAQ says the charge occurs after intake review and protocol approval, rather than when the order is first submitted. It does not separately settle the timing of every membership or consultation payment.

The terms require adults to be at least 18. They describe providers serving all 50 states, while also saying specific services vary with state rules. The telehealth disclaimer requires the patient to be physically located where the treating provider is licensed. Those qualifications matter more than a national availability badge; confirm both the selected product and the clinician’s authorization for your location.

The telehealth disclaimer limits the service to medication safety assessments and recommendations. It excludes primary care, urgent care and ongoing management of general medical conditions. Quarterly concierge check-ins are described, but the same document says they are not medical consultations. Readers seeking continuing care for a broader condition should obtain a clear description of clinical follow-up rather than treating concierge access as that service.

The homepage lists semaglutide at $279 and tirzepatide at $329 for a four-week supply. NAD+ and sermorelin each carry a $249 four-week label. Four weeks is 28 days, not a calendar month. These are advertised product amounts; they do not establish the complete initial payment or a price for every prescribed formulation and quantity.

Membership terms add a one-time initiation fee, with medication sold separately, but the fee amount is not stated in the reviewed terms. They describe medication purchases as needed without a recurring subscription, while reserving the possibility of a future subscription with notice and consent. A four-week supply should therefore not be presented as an automatic monthly debit. Ask whether the purchase being offered still follows the stated as-needed model.

The $50 optional video consultation is another distinct item. Its advertised credit does not establish that $50 is the initiation fee or that every charge disappears when an order is placed. An older telehealth disclaimer says consultations are included in the membership fee and are not separately billed. That wording needs to be reconciled with the current consultation offer. Request an itemized total showing membership, the consultation credit, medication, shipping and any other fees. Telehealth is explicitly self-pay under the disclaimer; do not assume an insurance reimbursement.

Cancellation is the largest conflict. The homepage FAQ says an order can be canceled or changed before it ships. The refund policy sets an earlier boundary: a cancellation may qualify for a full refund before physician consultation, clinical review and fulfillment work begin. It generally makes sales final once clinical review and fulfillment preparation have started. An order can still be unshipped after that point. Do not rely on shipment status alone; obtain the applicable deadline and the amount recoverable under the agreement for your order.

The policy separately promises a full refund of payments made if the clinical group does not approve the application. After shipment, prescription returns and refunds are restricted, with limited exceptions for damaged, defective or incorrect products. Those problems must be reported within 48 hours of delivery with order details and photographs; an approved replacement or refund is discretionary. Shipping fees are described as non-refundable. Confirmed lost shipments have a separate reshipment provision. These exceptions should not be turned into a general satisfaction guarantee.

The product pages describe subcutaneous injections. The GLP-1 pages leave total contents, concentration and vial size to the prescription, so the advertised four-week figure is not enough to compare vial quantities or dose-specific costs. The NAD+ page lists a 1,000 mg, 10 mL vial at 100 mg/mL; the sermorelin page lists 15 mg, 5 mL and 3 mg/mL. These are published product descriptions, not dosing instructions or confirmation of what an individual will receive.

The site states that compounded medications are not FDA-approved. Its testing presentation describes sterility, endotoxin, purity and strength checks, while the product disclaimer says PeptideCo does not independently verify testing results. A testing badge does not replace the assigned pharmacy’s product information or establish treatment benefit. Ask for the prescription label, supplying pharmacy and any available testing documentation tied to the supplied product.

The lower-dose listings and customer stories should not be treated as evidence that a particular protocol is appropriate or effective. This assessment concerns the offer, responsibilities and purchase terms; clinical suitability belongs with the treating professional.